Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, September 17, 2012 - Flucelvax


Submission Type: BLA    Submission ID: 125408/0    Office: OVRR
Influenza Virus Vaccine
Novartis Vaccines and Diagnostics, Inc.
Telecon Date/Time: 17-Sep-2012 04:00 PM        Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
1. Advice
Telecon Summary:
Reagents for testing of 2012-2013 vaccine
FDA Participants: Rajesh Gupta
Non-FDA Participants: Matthew Gollwitzer
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
CBER stated that they agree with the use of homologous H3N2 egg-based reagents; however, CBER does not recommend the use of heterologous reagents for B strain. This is based on CBER’s experience with discrepant results when heterologous reagents were used during the H1N1 pandemic.
While heterologous reagents for the H1N1 strain were re-calibrated by CBER, Novartis refused to test this year’s vaccine with the homologous B strain reagents, available from NIBSC. This caused a concern, particularly when Novartis has been using the homologous B strain reagents for releasing vaccine in Europe.
Novartis argued that they did not know if they could use reagents from NIBSC.
To move forward with this issue, CBER decided to test all lots with the homologous reagents B strain reagents for lot release at CBER.

Page Last Updated: 12/19/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English